MITRAL VALVE DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global mitral valve disease market is estimated to be valued at USD 3.06 Bn in 2025 and is expected to reach USD 5.67 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.2% from 2025 to 2032. Mitral valve disease refers to conditions that affect the mitral valve located between the left atrium and left ventricle of the heart. Mitral valve plays a key role in regulating blood flow from the left atrium to the left ventricle. Some common types of mitral valve disease include mitral valve stenosis, which causes narrowing or blockage of the mitral valve, and mitral valve regurgitation or insufficiency, which allows blood to flow backward through the mitral valve. Factors such as aging, rheumatic fever, congenital heart defects, and infections can damage the mitral valve and lead to diseases. Presently, there is no cure for mitral valve disease, however, treatments aim to repair or replace the damaged mitral valve via procedures such as mitral valve repair or replacement surgeries.

Market Dynamics

Global mitral valve disease market growth is driven by rising geriatric population globally who are more prone to develop mitral valve diseases due to age-related degeneration of heart valves. Increasing prevalence of rheumatic heart disease in developing nations can drive the market growth during the forecast period. However, high costs associated with mitral valve repair and replacement surgeries along with lack of skilled healthcare professionals can hamper the market growth. Ongoing development of novel mitral valve repair technologies and techniques present lucrative growth opportunities for market players.

Key Features of the Study

- This report provides in-depth analysis of the global mitral valve disease market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global mitral valve disease market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Edwards Lifesciences Corporation, Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, Corcym UK Limited, Artivion, Inc., ShockWave Medical, Inc., Valcare Medical, Braile Biomedica, Labcor Laboratorios Ltda, Zydus Lifesciences Limited, Affluent Medical, Teva Pharmaceutical Industries Ltd., Bayer AG, and Novartis AG

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global mitral valve disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mitral valve disease market

Market Segmentation

•  Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Mitral Valve Repair
    • Surgical Mitral Valve Repair
    • Transcatheter Mitral Valve Repair
  • Mitral Valve Replacement
    • Mechanical Valve Replacement
    • Biological Valve Replacement
    • Transcatheter Aortic Valve Replacement (TAVR)
  • Cardiac Resynchronization Therapy (CRT)
    • Biventricular Pacing
    • Implantable Cardioverter Defibrillators (ICDs)
  • Mitral Valve Therapeutics
    • Pharmacological Treatments
    • Device-Based Therapies
•  Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Mitral Valve Regurgitation
  • Mitral Valve Stenosis
  • Mitral Valve Prolapse
•  Device Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Surgical Instruments
    • Heart-Lung Machines
    • Surgical Staplers
    • Sutures
  • Implant Devices
    • Mitral Valve Prostheses
    • Repair Devices (e.g., annuloplasty rings)
    • Diagnostic Devices
    • Echocardiograms
    • Cardiac Imaging Systems
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Cardiac Rehabilitation Centers
  • Others
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
• Key Players Insights
  • Edwards Lifesciences Corporation
  • Medtronic Plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Corcym UK Limited
  • Artivion, Inc.
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Braile Biomedica
  • Labcor Laboratorios Ltda
  • Zydus Lifesciences Limited
  • Affluent Medical
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Novartis AG